ReviewJournal of clinical psychology in medical settings2026
Prevalence and Clinical Correlates of Avoidant/Restrictive Food Intake Disorder (ARFID) Among Patients with Inflammatory Bowel Disease: A Systematic Review.
Review in Journal of clinical psychology in medical settings, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avoidant/restrictive food intake disorder (ARFID) is an eating disorder characterized by inadequate or restricted food intake unrelated to body image or weight concerns. ARFID is frequently observed in patients with gastrointestinal disorders. Given the growing clinical interest, we conducted this systematic review to synthesize evidence, assessment approaches regarding ARFID-like symptomatology in adult patients with inflammatory bowel disease (IBD). A systematic search of MEDLINE, Scopus, Web of Science, PsycInfo was conducted in July 2025, yielding seven studies on ARFID in IBD. This review followed the framework outlined by Page (2021). Prevalence rates, assessment tools, associations with clinical, psychological factors were synthesized. Reported prevalence of ARFID-like behaviors ranged from 10.2 to 51.3%, reflecting differences in screening tools, cut-offs. Studies applying lower cut-offs (≥ 24) for the Nine Item ARFID Screen (NIAS) showed a weighted mean prevalence of 24, 2%, whereas stricter cut-offs (≥ 28) resulted in a a prevalence of 18, 6%, in line with the results from the Pica, ARFID, Rumination Disorder Interview-ARFID Questionnaire (PARDI-AR-Q). Higher ARFID levels were consistently linked to symptom-based clinical activity. Despite limited evidence, in some patients with normalized inflammatory markers, restrictive eating may persist, suggesting functional mechanisms beyond inflammation. Psychological distress, particularly anxiety, gastrointestinal-specific anxiety, was strongly associated with ARFID-like behaviors. The interplay between ARFID, symptom activity, psychological distress underscores the need for an integrated approach addressing gastroenterological, psychological, nutritional factors, aiming to improve ARFID screening, management in patients with IBD.
Indexed as
Identifiers
42321472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.